Pharmacological-toxicological Expert Report. Caelyx®. (Stealth® liposomal doxorubicin HCl)

Human and Experimental Toxicology

Volumn 15, Issue 9, 1996, Pages 751-785

  Working, Peter K ^a   Dayan, Anthony D ^b  

^a ALZA CORPORATION   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Caelyx ; Doxorubicin; Drug regulation; EC Expert Report; Liposome; Non clinical data

Indexed keywords

DOXORUBICIN; LIPOSOME; NEW DRUG; STEALTH; UNCLASSIFIED DRUG;

DRUG DEVELOPMENT; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG TOLERANCE; DRUG TOXICITY; MUTAGENICITY; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW; TOXICITY TESTING;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CHO CELLS; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; DOXORUBICIN; DRUG DELIVERY SYSTEMS; EMBRYONIC AND FETAL DEVELOPMENT; HUMANS; INJECTIONS, INTRAVENOUS; LIPOSOMES; MICE; MUTAGENICITY TESTS; NEOPLASMS, EXPERIMENTAL; PILOT PROJECTS; RABBITS; RATS; TISSUE DISTRIBUTION;

EID: 0029765442     PISSN: 01445952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. Lasic D & Martin F, eds. Stealth Liposomes. Boca Raton: CRC Press, 1995.
2. Benjamin RS, Wiernik PH & Bachur NR. Adriamycin chemotherapy-efficacy, safety, and pharmacologic basis of an intermittent singe high-dosage schedule. Cancer 1974; 33: 19-27.
3. Minow RA, Benjamin RS, Lee ET & Gottlieb JA. Adriamycin cardiomyopathy: Risk factors. Cancer 1977; 39: 1397-402.
4. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine 1979; 91: 710-7.
5. Maral RJ & Jouanne M. Toxicology of daunorubicin in animals and man. Cancer Treatment Reports 1981; 65 (Supplement 4): 9-18.
6. Wright JC. Cancer chemotherapy: Past, present and future - Part I. Journal of the National Medical Association 1984; 76: 773-84.
7. Legha SS, Hortobagyi GN & Benjamin RS (JJ Lokich, ed.) Anthracyclines. Cancer Chemotherapy by Infusion. Chicago: Precept Press, 1987 pp. 130-44.
8. Pigram WJ, Fuller W & Hamilton LD. Stereochemistry of intercalation. Interaction of daunomycin with DNA. Nature 1972; 235: 17-9.
9. Pindur U, Haber M & Sattler K. Antitumor active drugs as intercalates of deoxyribonucleic acid. Journal of Chemical Education 1993; 4: 263-72.
10. Zhang H, Gao Y, van de Marel GA & Wang AH-J. Simultaneous incorporations of two anticancer drugs into DNA. Journal of Biological Chemistry 1993; 268: 10095-101.
11. Hickman J, Chahwala SB & Thompson EG. Interaction of the antibiotic Adriamycin with the plasma membrane. Advances in Enzyme Regulation 1985; 24: 263-74.
12. Santone KS, Oakes SG, Taylor SR & Powis G. Anthracycline-induced inhibition of a calcium action potential in differentiated murine neuroblastoma cells. Cancer Research 1986; 46: 2659-64.
13. Pommier Y, Schwartz RE, Zwelling LA & Kohn KW. Effects of DNA intercalating agents on topoisomerase II induced DNA strand cleavage in isolated mammalian cell nuclei. Biochemistry 1985; 24: 6406-10.
14. Tewey KM, Rowe TC, Yang L, Halligan BD & Liu LF. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 1984; 226: 466-8.
15. Bachur NR, Gee MV & Gordon SL. Enzymatic activation of actinomycin D ACTD to free radical state. Proceedings of the American Association of Cancer Research 1978; 19: 75-9.
16. Berlin V & Haseltine WA. Reduction of Adriamycin to a semiquinone-free radical by NADPH cytochrome P-450 reductase produces DNA cleavage in a reaction mediated by molecular oxygen. Journal of Biological Chemistry 1981; 256: 4747-56.
17. Powis GP. Metabolism and reactions of quinoid anticancer agents. Pharmacological Therapeutics 1987; 35: 57-162.
18. Zwelling LA, Kerrigan D & Michael S. Cytotoxicity and DNA strand breaks by 5-iminodaunorubicin in mouse leukemia L1210 cells. Comparison with Adriamycin and 4′-9-acridinylamino methanesulfono-m-anisidine. Cancer Research 1982; 42: 2687-91.
19. Needham D, McIntosh TJ & Lasic DD. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochimica Biophysica Acta 1992; 1108: 40-8.
20. Dvorak HF, Nagy JA, Dvorak JT & Dvorak AM. Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. American Journal of Pathology 1988; 133: 95-109.
21. Wu NZ & Dewhirst MW. Measure of tissue uptake of intravenously injected macromolecules using fluorescence video-microscopy. Microvascular Research 1993; 46: 231-53.
22. Speth PAJ, van Hoesel QGCM & Haanen C. Clinical pharmacokinetics of doxorubicin. Clinical Pharmacokinetics 1988; 15: 15-31.
23. Greene RF, Collins JM, Jenkins JF, Speyer JL & Myers CE. Plasma pharmacokinetics of Adriamycin and Adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Research 1983; 43:43: 3417-21.
24. Speth PAJ, Linssen PCM, Holdrinet RSG & Haanen C. Plasma and cellular adriamycin concentrations in patients with myeloma treated with ninety-six-hour continuous infusion. Clinical Pharmacology and Therapeutics 1987; 41: 661-5.
25. Speth PAJ, Linssen PCM, Boezeman JBM, et al. Cellular and plasma Adriamycin concentrations in long-term infusion therapy of leukemia patients. Cancer Chemotherapy and Pharmacology 1987; 20: 305-10.
26. Yesair DW, Schwartzbach E, Shuck D, Denine EP & Asbell AS. Comparative pharmacokinetics of Daunomycin and Adriamycin in several animal species. Cancer Research 1972; 32: 1177-83.
27. Ozols RF, Locker GY, Doroshow JH, Grotzinger KR, Myers CE & Young RC. Pharmacokinetics of Adriamycin and tissue penetration in murine ovarian cancer. Cancer Research 1979; 39: 3209-14.
28. Oosterbaan MJ, Dirks RJ, Vree TB & van der Kleijn E. Pharmacokinetics of anthracyclines in dogs: evidence for structure-related body distribution and reduction to their hydroxy metabolites. Pharmaceutical Research 1984; 1: 33-8.
29. Cusack BJ, Young SP, Loseke VL, Hurty MR, Beals L & Olson RD. Effect of low-protein diet on doxorubicin pharmacokinetics in the rabbit. Cancer Chemotherapy and Pharmacology 1992; 30: 145-8.
30. Riggs CE, Benjamin RS, Serpick AA & Bachur NR. Biliary disposition of Adriamycin. Clinical Pharmacology and Therapeutics 1977; 22: 234-41.
31. Benjamin RS, Riggs CE & Bachur NR. Plasma pharmacokinetics of Adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Research 1977; 37: 1416-20.
32. Takanashi S & Bachur NR. Adriamycin metabolism in man, evidence for urinary metabolites. Drug Metabolism and Disposition 1976; 4: 79-87.
33. Gabizon A, Barenholz Y & Bialer M. Prolongation of the circulation time of doxorubicin encapsulated in liposomes containing a polyethyleneglycol-derivatized phospholipid: Pharmacokinetic studies in rodents and dogs. Pharmaceutical Research 1993; 10: 703-8.
34. Gabizon A, Catane R, Uziely B, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Research 1994; 54: 987-92.
35. Legha SS, Benjamin RS, Mackay B, et al. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer 1982; 49: 1762-6.
36. Lokich JJ & Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Annals of Internal Medicine 1984; 101: 798-800.
37. Vogelzang NJ & Ratain MJ. Cancer chemotherapy and skin changes. Annals of Internal Medicine 1985; 103: 303-4.
38. Riggs CE, Jr. & Bachur NR (MM Ames, G Powis, & JS Kovach, eds.) Clinical pharmacokinetics of anthracycline antibiotics. Pharmacokinetics of Anticancer Agents in Humans. Amsterdam and New York: Elsevier, 1983 pp. 229-78.
39. Johnson AH, Darpatkin HH & Newman J. Clinical investigation of intermediate- and high-purity antihaemophilic factor (factor VIII) concentrates. British Journal of Hematology 1971; 21: 21-41.
40. Shaffer CB & Critchfield FH. The absorption and excretion of the solid polyethylene glycols. Journal of the American Pharmacological Association 1947; 36: 152-7.
41. Carpenter CP, Woodside MD, Kinkead ER, King JM & Sullivan LJ. Response of dogs to repeated intravenous injection of polyethylene glycol 4000 with notes on excretion and sensitization. Toxicology and Applied Pharmacology 1971; 18: 35-40.
42. Jaenke RS. An anthracycline antibiotic-induced cardiomyopathy in rabbits. Laboratory Investigation 1974; 30: 292-304.
43. Iatropoulos MJ. Anthracycline cardiomyopathy: Predictive value of animal models. Cancer Treatment Symposium 1984; 3: 3-17.
44. Thompson D, Molello JA, Strebing RJ et al. Teratogenicity of Adriamycin and Daunomycin in the rat and rabbit. Teratology 1978; 17: 151-8.
45. Physicians' Desk Reference 45th Edition. Oradell NJ: Medical Economics Data, 1991, pp. 559-62.
46. Ansell GB, Dawson RMC & Hawthorne NJ. Form and Function of Phospholipids. Amsterdam: Elsevier, 1973.
47. Smyth HF, Carpenter CP & Weil CS. The chronic oral toxicity of the polyethylene glycols. Journal of the American Pharmacological Association 1950; 44: 27-30.
48. Freireich EJ et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, dog, monkey and man. Cancer Chemotherapy Reports 1966; 50: 219-44.
49. Wolf A, Saito T, Dudek R & Bing RJ. The effect of lysophosphatidylcholine on coronary and renal circulation in the rabbit. Lipids 1991; 26: 223-6.
50. Rudolph R, Stein RS & Pattillo RA. Skin ulcers due to Adriamycin. Cancer 1976; 38: 1087-94.
51. Samuels BL, Vogelzang NJ, Ruane M & Simon MA. Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treatment Reports 1987; 71: 971-2.
52. Ackland SP, Ratain MJ, Vogelzang NJ, Choi KE, Ruane M & Sinkule JA. Pharmacokinetics and pharmacodynamics of long-term continuous-infusion of doxorubicin. Clinical Pharmacology and Therapeutics 1989; 45: 340-7.
53. Dantchev D, Slioussartchouk V, Paintrand M, Hayat M, Bourut C & Mathe G. Electron microscopic studies of the heart and light microscopic studies of the skin after treatment of Golden hamsters with Adriamycin, Detorubicin, AD-32 and Aclacinomycin. Cancer Treatment Reports 1979; 63: 875-88.
54. Lu CC & Meistrich ML. Cytotoxic effects of chemotherapeutic drugs on mouse testis cells. Cancer Research 1979; 39: 3575-82.
55. Chapman RM, Sutcliffe SB, Rees LH, Edwards CRW & Malpas JS. Cyclical combination chemotherapy and gonadal function. Lancet 1979; 1: 285-9.
56. Whitehead E, Shalet SM, Blackledge G, Todd I, Crowhter D & Beardwell CG. The effects of Hodgkin's disease and combination chemotherapy on gonadal infusion in the adult male. Cancer 1982; 49: 418-22.
57. Fuse H, Iwasaki M & Katayama T. Endocrine/histological parameters of spermatogenic damage in doxorubicin-treated rats. Advances in Controlled Delivery Systems 1992; 8: 33-40.
58. Bertazzoli C, Chieli T, & Solcia E. Different incidence of breast carcinomas or fibroadenomas in Daunomycin or Adriamycin treated rats. Experientia 1971; 27: 1209-10.
59. Solcia E, Ballerini L, Bellini O, Sala L, & Bertazzoli C. Mammary tumors induced in rats by Adriamycin and Daunomycin. Cancer Research 1978; 38: 1444-6.
60. Gabizon A, Amselem S, Goren D, et al. Preclinical and clinical experience with a doxorubicin-liposome preparation. Journal of Liposome Research 1990; 1: 491-502.
61. Gabizon A, Chisin R, Amselem S et al. Pharmacokinetic and imaging studies in patients receiving a formulation of liposome-associated adriamycin. British Journal of Cancer 1991; 64: 1125-32.
62. Wu NZ, Da D, Rudoll TL, Needham D, Whorton AR & Dewhirst MW. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Research 1993; 53: 3765-70.
63. Huang SK, Lee K-D, Hong D, Friend DS & Papahadjopoulos D. Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Research 1992; 52: 5135-43.
64. Huang SK, Martin FJ, Jay G, Vogel J, Papahadjopoulos D & Friend DS. Extravasation and transcytosis of liposomes in Kaposi's Sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. American Journal of Pathology 1993; 143: 10-14.
65. Woodle MC & Lasic DD. Sterically stabilized liposome. Biochimica Biophysica Acta 1992; 1113: 171-99.
66. Chlebowski RT, Paroly WS, Pugh RP, et al. Adriainycin given as a weekly schedule without a loading course: Clinically effective with reduced incidence cardiotoxicity. Cancer Treatment Reports 1980; 64: 47-51.
67. Lokich JJ, Bothe A, Zipoli T et al. Constant infusion schedule for Adriamycin: A phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system. Journal of Clinical Oncology 1983; 1: 24-8.
68. Tietz NW. Clinical Chemistry. Philadelphia: WB Saunders Company, 1986.